Ciloa is dedicated to the development of new high potential therapies. It was built on more than 15 years of research on bio-drug development technology using exosomes.

Ciloa’s technology allows to address oncology, infectiology, cardiology, genetic and neurological diseases, and more.

Our technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It thus makes it possible to reach the most difficult families of membrane protein targets, known as “undruggable”, some being the most promising for therapies.

Ciloa takes advantage of the natural properties of exosomes; they are natural immuno-stimulators, biocompatible, intercellular membrane messengers, and able to cross all the human body barriers including the blood-brain barrier.